5440672025-04-012025-06-305440672025-06-305440672025-04-012025-06-30in-capmkt:OtherExpenses1Member5440672025-04-012025-06-30in-capmkt:OtherExpenses2Member5440672025-04-012025-06-30in-capmkt:OtherExpenses3Member5440672025-04-012025-06-30in-capmkt:OtherExpenses4Member5440672025-04-012025-06-30in-capmkt:OtherExpenses5Member5440672025-04-012025-06-30in-capmkt:OtherExpenses6Member5440672025-04-012025-06-30in-capmkt:OtherExpenses7Member5440672025-04-012025-06-30in-capmkt:OtherExpenses8Member5440672025-04-012025-06-30in-capmkt:OtherExpenses9Member5440672025-04-012025-06-30in-capmkt:OtherExpenses10Member5440672025-04-012025-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15440672025-06-30Statement15440672025-04-012025-06-30Statement15440672025-06-30StatementDynamic1I1Statement15440672025-06-30StatementDynamic1I2Statement15440672025-06-30StatementDynamic1I3Statement15440672025-06-30StatementDynamic1I4Statement1iso4217:INRxbrli:pureiso4217:INRxbrli:shares544067INNOVACAPNOTLISTEDINE0DUT01020INNOVA CAPTAB LIMITEDMain BoardEquity2025-04-012026-03-312025-08-072025-07-30INRMillionsQuarterlyFirst quarterSingle segmentDrugs and Pharmaceutical products2025-08-0715:30:002025-08-0716:35:00Not applicabletrue1true2025-04-012025-06-30UnauditedStandalone2869790000431500002912940000203464000012820000-1082000025345000027680000907600002314900002640020000272920000027292000051220000187500006997000002029500000000202950000-2720000200230000572250000103.553.55003.553.55The above standalone financial results of Innova Captab Limited have been prepared in accordance with and comply in all material aspects with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013 read with relevant rules issued there under and in terms of Regulation 33 of Securities and Exchange Board of India Listing Obligations and Disclosure Requirements Regulations 2015 Listing Regulation as amended The results for the quarter ended 30 June 2025 are available on the Company website under investor information section and on the stock exchange website <BR> The above standalone financial results have been reviewed and recommended by Audit Committee at its meeting held on 07 August 2025 the Board of Directors at their meeting held on 07 August 2025 have approved the above results and taken them on record The statutory auditors of the Company have expressed an unmodified review conclusion on the standalone financial results for the quarter ended 30 June 2025 <BR> <BR> The Company has only one reportable segment ie Drugs and pharmaceutical product as per Ind AS 108 Operating Segments specified under section 133 of the Companies Act 2013 Accordingly the disclosures as per the listing agreement are not applicable to the group <BR> <BR> The figures of the last quarter ended 31 March 2025 as reported in these standalone financial results are the balancing figures between audited figures in respect of full financial year and the unaudited published year to date figures up to the third quarter of the relevant financial year Also the figures upto the end of the third quarter had only been reviewed and not subject to audit <BR> Power and fuel62760000Stores and spares consumed33950000Repairs and maintenance17430000Packing charges30680000Lab consumables9890000Legal and professional fee8000000CSR expenditure4860000Rates, fees and taxes8280000Freight charges10220000Other expenses45420000 <BR> The Company has only one reportable segment ie Drugs and pharmaceutical products as per IndAS 108 Operating Segments specified under section 133 of the Companies Act 2013 Accordingly the disclosures as per the listing agreement are not applicable to the group <BR> Remeasurement of defined benefit obligation-3640000-3640000-9200000-272000000000Public Issues2023-12-2732000000002025-06-30trueCRISIL Ratings LimitedfalseNot ApplicableNo CommentsNo CommentsNeeharika ShuklaCompany Secretary and Compliance OfficerPanchkula2025-08-07Repayment and/or prepayment, in part or in full, of certain outstanding loansof the companyNot Applicable1444000000014440000000Investment in the subsidiary, UML, for repayments and/or prepayment n part or full of outstandng loans availed by UMLNot Applicable23600000002360000000funding working capital requirements of the companyNot Applicable72000000007200000000general corporate purposesNot Applicable53109000005421800000The Board may take note that total expenditure initially estimated in connection with the Company Initial Public Offering amounted to Rs 479 million Subsequently the actual costs incurred were Rs 452 million thereby resulting in a net reduction in cost of Rs 27 million Out of this a sum of Rs 16 million is attributable to the selling shareholder for which the requisite payment has been duly remitted as of 30th June 2025 The residual balance of Rs 11 million pertaining to the Company has been appropriately allocated towards general corporate purposes Further as per the Object of the Offer approved if the actual utilization towards any of the stated objects is lower than the proposed deployment the balance shall be utilized for general corporate purposes This is subject to the condition that the total amount allocated towards general corporate purposes shall not exceed 25 percent of the gross proceeds from the Fresh Issue in accordance with applicable Regulation <br></br>